Search Results
Apr 24, 2026, 02:02 ET German manufacturer infringes patent of Brazilian polyurethane breast implant technology - court grants Silimed preliminary injunction
manufacturing, distributing, and marketing polyurethane (PU) silicone breast implants in Germany using Silimed® patented technology according to European Patent EP 2 582 193 B1. Failure to comply will result in up to a 250,000 Euro for each breach by Polytech or up to six months of imprisonment, or up to two years
More news about: Silimed
Apr 24, 2026, 02:02 ET Deutscher Hersteller verletzt Patent auf brasilianische Technologie für Polyurethan-Brustimplantate - Gericht erlässt einstweilige Verfügung zugunsten von Silimed
(PU)-beschichteten Silikon-Brustimplantaten in Deutschland unter Verwendung der patentierten Technologie von Silimed® nach dem europäischen Patent EP 2 582 193 B1 mit sofortiger Wirkung einzustellen. Bei Nichtbeachtung drohen Polytech für jeden Verstoß ein Ordnungsgeld
More news about: Silimed
Apr 23, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Alleged Concealment of Electrophysiology Demand Weaknesses: SueWallSt
and adjusted EPS of $3.02 to $3.04 as late as October 22, 2025. The complaint asserts that these projections were issued while adverse trends in U.S. EP procedure volumes, competitive dynamics, and reimbursement headwinds were already affecting the segment's trajectory."Institutional investors
More news about: SueWallSt.com
Apr 23, 2026, 08:00 ET Immunic, Inc. Announces 1-for-10 Reverse Stock Split
split-adjusted basis at the opening of the Nasdaq Capital Market on April 27, 2026. The new CUSIP number for the split-adjusted common stock will be 4525EP200.At the Company's special meeting of stockholders on April 14, 2026, the stockholders approved a proposal to amend the Company's certificate
More news about: Immunic, Inc.
Apr 22, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth: Levi & Korsinsky
During the accompanying earnings call, management described 94% EP sales growth and characterized the quarter as "exceptional top-line performance." The lawsuit contends that management projected "continued high single-digit growth" in EP for the second half of 2025 while allegedly aware
More news about: Levi & Korsinsky, LLP
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
are sponsored and led by MSD.About A400/EP0031A400/EP0031 novel next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of A400/EP0031 has been accepted for review by the Center
More news about: Kelun-Biotech
Apr 21, 2026, 20:28 ET 2026 ASCO | 科倫博泰3項研究成果入選2026美國臨床腫瘤學會年會口頭彙報
科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)將在本次大會公佈TROP2 ADC蘆康沙妥珠單抗(sac-TMT，佳泰萊®)、下一代選擇性RET抑制劑富馬酸侖博替尼(A400/EP0031，寧泰萊®[1])以及新型ADC SKB500的三項臨床研究結果，相關研究摘要全文將於當地時間2026年5月21日發佈在 ASCO
More news about: 科倫博泰
Apr 21, 2026, 09:50 ET BSX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: Faruqi & Faruqi, LLP
Apr 21, 2026, 09:00 ET BSX Shareholder Alert: May 4, 2026 Lead Plaintiff Deadline in Boston Scientific Corporation Securities Class Action Lawsuit -- The Gross Law Firm
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: The Gross Law Firm
Apr 21, 2026, 07:00 ET Corify Care Validates 4-D Global Cardiac Mapping for Complex Atrial and Ventricular Arrhythmias
instantly, the ACORYS® mapping system provides actionable insight before ablation begins."Time and predictability are the most valuable assets in the EP lab," said Andreu Climent, PhD, CEO of Corify Care. "These publications prove that we can give physicians the full picture upfront, without delay.
More news about: Corify Care
Apr 21, 2026, 06:00 ET LUMA Vision to Showcase VERAFEYE 4D Imaging Platform at HRS 2026, Signaling a New Foundation for EP Guidance
seconds, supporting faster, more intuitive, and more precise procedures.VERAEYE is redefining EP Guidance — from tools to platform, VERAFEYE is designed to eliminate the fragmentation of current EP workflows by enabling physicians to see and guide therapy in real time, rather than relying on the
More news about: LUMA Vision
Apr 20, 2026, 16:45 ET CHAGEE Partners with Laufey as Brand Accelerates U.S. Expansion
between Reykjavik and Washington, D.C., she learned piano and cello as a child, later studying at Berklee College of Music. There, she wrote her debut EP, 2021's Typical of Me, whose striking single "Street by Street" debuted at #1 on Icelandic radio—the first of many achievements that have grown
More news about: CHAGEE
Apr 20, 2026, 08:00 ET HEART RHYTHM 2026: THE WORLD'S LEADING EP EVENT RETURNS FOR ITS 47TH YEAR, UNVEILING CUTTING-EDGE SCIENCE SHAPING THE FUTURE OF ARRHYTHMIA CARE
Electrophysiologists from around the globe convene in Chicago to break new ground in the field of EPCHICAGO, April 20, 2026 /PRNewswire/ -- The 47th Annual Heart Rhythm Society (HRS) meeting kicks
More news about: Heart Rhythm Society
Apr 17, 2026, 15:32 ET Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
alleges that, between July 23, 2025 and February 3, 2026, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing
More news about: Law Offices of Howard G. Smith
Apr 17, 2026, 08:49 ET BSX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: Faruqi & Faruqi, LLP
Apr 17, 2026, 08:00 ET Corify Care Receives FDA Clearance for ACORYS® -- Introducing Instant, 4-D Electroanatomical Cardiac Mapping in Real-time
mapping. This instant, whole-heart functional insight enables faster, safer, and more predictable ablation procedures.Designed to complement modern EP workflows, ACORYS empowers physicians with real-time, panoramic mapping of complex arrhythmia mechanisms. This approach allows clinical teams to gain
More news about: Corify Care
Apr 16, 2026, 11:05 ET INVESTOR DEADLINE: Boston Scientific Corporation (BSX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
minimizing risk from seasonality and macroeconomic fluctuations; and (ii) Boston Scientific's ambition of continuing "to grow our share in the overall EP market" to maintain a growth trajectory at "2x the market" had fallen short of reality because Boston Scientific had begun to experience new competition
More news about: Robbins Geller Rudman & Dowd LLP
Apr 16, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting Electrophysiology Procedure Growth: SueWallSt
During the accompanying earnings call, management described 94% EP sales growth and characterized the quarter as "exceptional top-line performance." The lawsuit contends that management projected "continued high single-digit growth" in EP for the second half of 2025 while allegedly aware
More news about: SueWallSt.com
Apr 16, 2026, 08:00 ET ZeroEyes Public Safety Alerts with Samdesk Integration for Real-Time Risk Detection and Awareness Now Available
Safety Alerts supports a wide range of security and operational functions, including Global Security Operations Centers (GSOC), Executive Protection (EP), Travel Risk Management (TRM), campus safety, and public safety teams. By consolidating fragmented intelligence sources into a single, trusted feed,
More news about: ZeroEyes
Apr 15, 2026, 15:00 ET ENGWE Marks 12th Anniversary with Major US Sale and All-New 3.0 Series Debut
EP-2 3.0For the practical commuter, the EP-2 3.0 debuts today as the "Most Efficient Beast
More news about: ENGWE
Apr 15, 2026, 09:00 ET BSX Investor Alert: BOSTON SCIENTIFIC CORPORATION Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Claims Executives Misrepresented U.S. Electrophysiology Volumes: Levi & Korsinsky
Headwinds by the NumbersThe filing states that management repeatedly characterized the EP market as the "largest" and "fastest growing" in medtech while concealing adverse trends:The EP segment reported 94% sales growth in Q2 2025 while lapping the initial FARAPULSE U.S. launch,
More news about: Levi & Korsinsky, LLP
Apr 14, 2026, 17:25 ET Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
alleges that, between July 23, 2025 and February 3, 2026, Defendants failed to disclose to investors that: (1) Boston Scientific's U.S. EP segment's growth rate was unsustainable and was approaching an earlier tipping point than the market was anticipating; (2) the Company was experiencing
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Apr 14, 2026, 09:00 ET BSX Shareholder Alert: Boston Scientific Corporation Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm
disappointment in U.S. EP sales, and issued guidance for fiscal 2026 that fell well below expectations. The Company attributed its results and dismal guidance on a combination of slower than expected market growth alongside increased competition, despite management's previous claims of a "growing" EP business and
More news about: The Gross Law Firm
Apr 14, 2026, 03:49 ET CS Analytical Names Jennifer Roark to Director of Scientific Affairs
medical device industries, the CS Analytical Team includes world-leading experts and thought-leaders on FDA and EU regulatory expectations and USP and EP primary package testing requirements inclusive of
More news about: CS Analytical
Apr 13, 2026, 08:24 ET Ada Health Patents the Clinical Layer That Makes LLMs Safe for Healthcare
pharma, health systems, and payers partners, where safety and explainability are prerequisites.About the PatentThe patent (EP4679451B1) covering Ada Health's hybrid architecture was officially granted by the European Patent Office and went into effect on March 25, 2026, with a priority
More news about: Ada Health